Plain-English translation of NCT07148297 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The CASCADE study is testing a new blood test technology that looks for specific cancer signals in your blood to detect colorectal cancer. Researchers will collect blood samples and, if applicable, tissue samples from people who have been diagnosed with colorectal cancer and from people who have had normal colonoscopy results. The goal is to see how well this new test can identify colorectal cancer by comparing the results between these two groups.
Colorectal cancer is often found late, when it's harder to treat. Researchers are developing this blood test as a potential way to catch the disease earlier, before symptoms appear, which could save lives.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be asked to provide a blood sample (taken from your vein) and possibly a tissue sample, either before your colonoscopy or surgery or during the procedure itself. The study is observational, meaning researchers will collect these samples and analyze them—you won't be taking a new medication or undergoing a new treatment as part of this trial. Your participation helps researchers understand how well this new blood test works at detecting cancer.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Argentina
Sponsor
Epiliquid Holding, Inc
Enrollment target
~600 participants
Started
June 2021
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
45 Years – 75 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr. Victoria Bocanegra, MD, PhD.
Epiliquid Holding, Inc
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.